RNA標的低分子創薬市場- 世界の産業規模、シェア、動向、機会、2018～2028年予測

世界のRNA標的低分子創薬市場は、予測期間中に目覚ましい成長を遂げると予測されています。

この背景には、がん、遺伝性疾患、ウイルス感染などの疾病の蔓延の増加、製薬・バイオテクノロジー企業による研究開発活動への支出の増加があります。また、主要な市場参入企業の存在感の高まり、先進的な医療インフラ、研究開発活動への投資の増加は、予測期間中に有利な成長を生み出すと予想されます。同様に、新しい治療法の開発と商業化を支援する、確立された医療システムが成長していることも、長年にわたる市場の成長を促進する主な要因です。実際、2020年にUSFDAが承認した医薬品は55品目で、そのうち65％以上が低分子治療薬でした。特筆すべきは、これらの医薬品の大半が、従来はタンパク質を標的として開発されていたことです。

RNA関連疾患の増加

RNA関連疾患の有病率の増加は、世界のRNA標的低分子創薬市場の成長促進要因の一つです。RNAは様々な細胞内プロセスにおいて重要な役割を果たしており、RNA機能の調節不全は、がん、遺伝性疾患、ウイルス感染などの様々な疾患を引き起こす可能性があります。これらの疾患の有病率は増加しており、RNA標的低分子医薬品の需要が高まっています。RNA標的小分子薬は、RNA関連疾患の治療に有望なアプローチです。低分子は特定のRNA標的に選択的に結合し、その活性を調節することができるため、RNAの調節異常によって引き起こされる疾患に対する潜在的な治療アプローチを提供します。例えば、RNAを標的とした低分子薬剤は、特に従来の化学療法が有効でない場合のがん治療において有望な結果を示しています。また、嚢胞性線維症など、RNAの異常によって引き起こされる遺伝性疾患の治療にも可能性が示されています。RNA関連疾患の増加により、RNAを標的とした低分子創薬研究に注目が集まっています。多くの製薬会社、新興企業、研究機関がこの分野に多額の投資を行っており、これが市場成長の原動力となっています。

RNA生物学の進歩

RNA生物学の進歩は、世界のRNA標的低分子創薬市場の成長に重要な役割を果たしています。ハイスループットシークエンシングや遺伝子編集などの技術の進歩により、RNA生物学に対する理解が著しく深まっています。その結果、新たなRNA標的が同定され、新規のRNA標的低分子医薬品の開発につながっています。RNA生物学の進歩により、研究者はRNA分子が疾病に関与するメカニズムをより深く理解できるようになっています。この理解は、以前は未知であった、あるいは十分に理解されていなかった新しいRNA標的の同定につながっています。新たなRNA標的の発見は、創薬の新たな機会を開き、新規のRNA標的低分子医薬品の開発につながっています。さらに、RNA生物学の進歩は、RNA標的低分子創薬のための新しい技術やツールの開発につながっています。例えば、ハイスループットスクリーニング技術の進歩により、研究者は大量の化合物ライブラリーをスクリーニングし、潜在的なRNA標的薬を迅速に同定できるようになっています。これにより創薬プロセスが加速され、より効率的な新薬開発が可能になっています。RNA生物学の進歩により、特異性と効力が改善されたRNA標的低分子医薬品の開発も可能になっています。RNA分子の構造と機能を理解することにより、研究者は特定のRNA標的に選択的に結合し、その活性を調節する低分子を設計することができます。

RNA標的創薬研究への資金提供の増加

RNA標的創薬研究に対する資金提供の増加は、世界のRNA標的低分子創薬市場の成長に大きな影響を与えています。RNA標的低分子医薬品は、がん、遺伝性疾患、ウイルス感染症を含む様々な疾患の治療に有望なアプローチを提供します。しかし、こうした医薬品の開発は複雑なプロセスであり、研究開発に多額の投資を必要とします。RNAを標的とした創薬研究への資金援助を増やすことは、創薬プロセスを加速させ、成功の可能性を高めることにつながります。RNA標的の同定と検証、新しいスクリーニング技術の開発、低分子化合物の設計、前臨床試験や臨床試験の実施などの研究開発を支援することができます。さらに、資金援助が増えれば、この分野に一流の研究者や科学者を引きつけることができ、RNA標的創薬研究の革新と飛躍的進歩につながります。また、資金調達が可能になれば、学術界と産業界のコラボレーションが促進され、より効率的で効果的な創薬プロセスにつながります。政府、非営利団体、製薬会社を含むいくつかの組織が、RNA標的創薬研究に多額の投資を行っています。例えば、米国国立衛生研究所（NIH）は、RNAに焦点を当てたAccelerating Medicines PartnershipやBlueprint Neurotherapeutics Networkなど、RNAを標的とした創薬の加速を目的としたいくつかのイニシアチブを立ち上げています。これらのイニシアチブは、この分野の研究者に多大な資金とリソースを提供しています。

個別化医療への需要の高まり

個別化医療に対する需要の高まりは、世界のRNA標的低分子創薬市場の成長にとって重要な促進要因です。個別化医療は、遺伝的体質、ライフスタイル、環境などを考慮し、患者一人ひとりの特性に合わせた医療を目指すものです。RNA標的低分子医薬品は、患者の疾患に関与する特定のRNA分子を選択的に標的とすることができるため、個別化医療の有望なアプローチとなります。RNA標的低分子医薬品は、個々の患者の遺伝子プロファイルに特異的に設計することができ、より効果的な治療と患者の転帰の改善につながります。例えば、がん患者は、腫瘍の成長を促進する特定の変異をRNAに持っているかもしれないです。RNA標的小分子薬は、この変異を特異的に標的とするように設計することができ、より効果的な治療と副作用の軽減につながります。さらに、RNA標的低分子医薬品は、特定のRNA異常によって引き起こされる希少疾患の治療にも使用できます。これらの薬剤は少量から開発・製造できるため、個別化医療に最適です。個別化医療に対する需要の高まりは、ゲノム医療の進歩、より個別化された治療に対する患者の意識と需要の高まり、個別化治療の開発・製造技術の向上など、いくつかの要因によってもたらされています。多くの製薬会社や新興企業は、個別化医療に対する需要の高まりに対応するため、RNA標的低分子創薬研究に投資しています。これらの企業は、RNA生物学、ハイスループットスクリーニング技術、計算手法の進歩を活用して、個別化RNA標的低分子医薬品の開発に取り組んでいます。

最近の進展

• 2021年、米国FDAは、原発性高シュウ酸尿症1型の治療薬として、初のRNA標的低分子医薬品ルマシランを承認しました。ルマシランは、この稀な遺伝性疾患の患者に蓄積するシュウ酸塩を産生する酵素をコードするRNAを標的として分解します。今回の承認は、RNA標的創薬分野にとって重要なマイルストーンとなります。
• 2020年、Alnylam Pharmaceuticalsは米国FDAから承認された初のRNA標的低分子医薬品であるルマシランを発売しました。ルマシランは、腎障害や腎不全を引き起こすまれな遺伝性疾患である原発性高シュウ酸尿症1型の治療に適応されます。
• 2019年、Alnylam Pharmaceuticalsは、急性肝性ポルフィリン症の治療薬としてRNA標的低分子医薬品ジボシランを発売しました。ジボシランは、このまれな遺伝性疾患の患者において、有毒なヘム中間体を産生する酵素をコードするRNAを標的として分解することにより作用します。
• 2021年、Novartisは高コレステロール治療用のRNA標的低分子医薬品であるインクリシランを上市しました。インクリシランは、血液中のコレステロール値を調節するタンパク質であるPCSK9をコードするRNAを標的として分解します。

調査範囲：

本レポートでは、世界のRNA標的低分子創薬市場を、以下に詳述する業界動向に加えて、以下のカテゴリーに分類している：

RNA標的低分子創薬市場、適応症別

• がん
• 感染症
• 代謝性疾患
• 神経疾患
• その他

RNA標的低分子創薬市場：エンドユーザー別

• 製薬・バイオ医薬品企業
• 学術・研究機関
• その他

RNA標的低分子創薬市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
• 南米
  • ブラジル
  • アルゼンチン
  • コロンビア
• 中東＆アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

競合情勢

企業プロファイル：世界のRNA標的低分子創薬市場に参入している主要企業の詳細分析

利用可能なカスタマイズ：

TechSci Research社は、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です。

企業情報

• 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 RNA標的低分子創薬の世界市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 適応症別（がん、感染症、代謝性疾患、神経疾患、その他）
  • エンドユーザー別（製薬・バイオ医薬品企業、学術・研究機関、その他）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2022年）
• 市場マップ
  • 適応症別
  • エンドユーザー別
  • 地域別

第6章 北米のRNA標的低分子創薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のRNA標的低分子創薬市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋のRNA標的低分子創薬市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のRNA標的低分子創薬市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのRNA標的低分子創薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品発表

第13章 世界のRNA標的低分子創薬市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Accent Therapeutics.
• Anima Biotech Inc.
• Arrakis Therapeutics.
• AstraZeneca Plc.
• Epics Therapeutics.
• Expansion Therapeutics.
• F. Hoffmann-La Roche Ltd.
• H3 Biomedicine Inc.
• PTC Therapeutics.
• Ribometrix.
• Servier Laboratories.
• Skyhawk Therapeutics, Inc.

第16章 戦略的提言

The Global RNA Targeting Small Molecule Drug Discovery Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the increasing prevalence of diseases such as cancer, genetic disorders, and viral infections and rising expenditure in R&D activities by pharmaceutical and biotechnology businesses. Also, the growing presence of key market players, advanced healthcare infrastructure, and increasing investment in research and development activities are expected to create lucrative growth during the forecast period. Similarly, a growing well-established healthcare system that supports the development and commercialization of new therapies is also a major factor fuelling the growth of the market over the years. In fact, in 2020, the USFDA approved 55 drugs, of which, over 65% were small molecule therapeutics. It is worth noting that majority of these drugs were conventionally developed to target proteins.

Increasing Prevalence of RNA-Related Diseases

The increasing prevalence of RNA-related diseases is one of the key drivers of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. RNA plays a critical role in various cellular processes, and dysregulation of RNA function can lead to various diseases, including cancer, genetic disorders, and viral infections. The prevalence of these diseases is increasing, leading to a growing demand for RNA-targeted small molecule drugs. RNA-targeted small molecule drugs offer a promising approach for the treatment of RNA-related diseases. Small molecules can selectively bind to specific RNA targets and modulate their activity, offering a potential therapeutic approach for diseases caused by RNA dysregulation. For example, RNA-targeted small molecule drugs have shown promising results in the treatment of cancer, particularly in cases where traditional chemotherapy is not effective. They have also shown potential for the treatment of genetic disorders caused by RNA abnormalities, such as cystic fibrosis. The increasing prevalence of RNA-related diseases has led to an increased focus on RNA-targeted small molecule drug discovery research. Many pharmaceutical companies, startups, and research institutions are investing heavily in this area, which is driving the growth of the market.

Advancements in RNA Biology

Advancements in RNA biology have played a significant role in the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. With the advancement of technologies, including high-throughput sequencing and gene editing, the understanding of RNA biology has increased significantly. This has led to the identification of new RNA targets and the development of novel RNA-targeted small molecule drugs. Advancements in RNA biology have enabled researchers to better understand the mechanisms by which RNA molecules contribute to disease. This understanding has led to the identification of new RNA targets that were previously unknown or poorly understood. The discovery of new RNA targets has opened up new opportunities for drug discovery, leading to the development of novel RNA-targeted small molecule drugs. Furthermore, advancements in RNA biology have led to the development of new technologies and tools for RNA-targeted small molecule drug discovery. For example, advances in high-throughput screening technologies have enabled researchers to screen large libraries of compounds to identify potential RNA-targeted drugs quickly. This has accelerated the drug discovery process and enabled the development of new drugs more efficiently. Advancements in RNA biology have also enabled the development of RNA-targeted small molecule drugs with improved specificity and potency. By understanding the structure and function of RNA molecules, researchers can design small molecules that selectively bind to specific RNA targets and modulate their activity.

Increased Funding for RNA-Targeted Drug Discovery Research

Increased funding for RNA-targeted drug discovery research has a significant impact on the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. RNA-targeted small molecule drugs offer a promising approach for the treatment of various diseases, including cancer, genetic disorders, and viral infections. However, developing these drugs is a complex process that requires significant investment in research and development. Increased funding for RNA-targeted drug discovery research can help to accelerate the drug discovery process and improve the chances of success. Funding can support research in identifying and validating RNA targets, developing new screening technologies, designing small molecules, and conducting preclinical and clinical studies. Furthermore, increased funding can help to attract top researchers and scientists to the field, leading to more innovation and breakthroughs in RNA-targeted drug discovery research. The availability of funding can also encourage collaborations between academia and industry, leading to more efficient and effective drug discovery processes. Several organizations, including governments, non-profit organizations, and pharmaceutical companies, are investing heavily in RNA-targeted drug discovery research. For example, the US National Institutes of Health (NIH) has launched several initiatives aimed at accelerating RNA-targeted drug discovery, including the RNA-focused Accelerating Medicines Partnership and the Blueprint Neurotherapeutics Network. These initiatives provide significant funding and resources for researchers working in the field.

Growing Demand for Personalized Medicine

The growing demand for personalized medicine is a significant driver of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. Personalized medicine aims to tailor medical treatment to the individual characteristics of each patient, taking into account their genetic makeup, lifestyle, and environment. RNA-targeted small molecule drugs offer a promising approach for personalized medicine, as they can selectively target specific RNA molecules that are involved in a patient's disease. RNA-targeted small molecule drugs can be designed to be specific to individual patients' genetic profiles, leading to more effective treatments and better patient outcomes. For example, a patient with cancer may have a specific mutation in their RNA that is driving the growth of their tumor. RNA-targeted small molecule drugs can be designed to specifically target this mutation, leading to more effective treatment and fewer side effects. Furthermore, RNA-targeted small molecule drugs can be used to treat rare diseases caused by specific RNA abnormalities. These drugs can be developed and manufactured in small quantities, making them ideal for personalized medicine. The growing demand for personalized medicine is driven by several factors, including advances in genomic medicine, increasing patient awareness and demand for more personalized care, and improvements in technology for developing and manufacturing personalized therapies. Many pharmaceutical companies and startups are investing in RNA-targeted small molecule drug discovery research to meet the growing demand for personalized medicine. These companies are leveraging advancements in RNA biology, high-throughput screening technologies, and computational methods to develop personalized RNA-targeted small molecule drugs.

Rise in the Number of Startups and Small Companies Focusing on RNA-Targeted Drug Discovery

The rise in the number of startups and small companies focusing on RNA-targeted drug discovery is a significant driver of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. Startups and small companies are playing a crucial role in advancing RNA-targeted drug discovery research and bringing innovative therapies to the market. Startups and small companies are often more agile and able to quickly adopt new technologies and approaches to drug discovery. These companies can focus on niche areas of RNA biology, allowing them to identify and develop RNA targets that may have been overlooked by larger pharmaceutical companies. Furthermore, startups and small companies are increasingly receiving funding and support from venture capitalists, government agencies, and non-profit organizations. This funding allows these companies to invest in research and development and advance their pipeline of RNA-targeted small molecule drugs. The rise of startups and small companies in the RNA-targeted drug discovery space is also leading to increased competition, which is driving innovation and improving the efficiency of the drug discovery process. This competition is also leading to the development of more affordable and accessible RNA-targeted small molecule drugs, which can benefit patients globally. Several startups and small companies focusing on RNA-targeted drug discovery have already made significant advances in the field. These companies have developed innovative screening platforms, identified novel RNA targets, and advanced promising RNA-targeted small molecule drugs into preclinical and clinical trials.

Recent Development

• In 2021, the US FDA approved the first RNA-targeted small molecule drug, Lumasiran, for the treatment of primary hyperoxaluria type 1. Lumasiran targets and degrades the RNA that encodes the enzyme responsible for producing oxalate, which accumulates in patients with this rare genetic disease. This approval represents a significant milestone for the RNA-targeted drug discovery field.
• In 2020, Alnylam Pharmaceuticals launched Lumasiran, the first RNA-targeting small molecule drug approved by the US FDA. Lumasiran is indicated for the treatment of primary hyperoxaluria type 1, a rare genetic disorder that can lead to kidney damage and failure.
• In 2019, Alnylam Pharmaceuticals launched Givosiran, an RNA-targeting small molecule drug for the treatment of acute hepatic porphyria. Givosiran works by targeting and degrading the RNA that encodes the enzyme responsible for producing toxic heme intermediates in patients with this rare genetic disease.
• In 2021, Novartis launched Inclisiran, an RNA-targeting small molecule drug for the treatment of high cholesterol. Inclisiran targets and degrades the RNA that encodes for PCSK9, a protein that regulates cholesterol levels in the blood.

Market Segmentation

Global RNA Targeting Small Molecule Drug Discovery market can be segmented by Indication, End Users, Region and Competitive Landscape. Based on the indication, the market can be segmented into Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others. Based on end users, the market can be differentiated into Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others.

Market Players

Accent Therapeutics., Anima Biotech Inc., Arrakis Therapeutics., AstraZeneca., Epics Therapeutics., Expansion Therapeutics., Hoffmann-La Roche Ltd., H3 Biomedicine Inc., PTC Therapeutics., Ribometrix., Servier Laboratories., Skyhawk Therapeutics, Inc. are some of the leading players operating in the Global RNATargeting Small Molecule Drug Discovery Market.

Report Scope:

In this report, Global RNA Targeting Small Molecule Drug Discovery market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Targeting Small Molecule Drug Discovery Market, By Indication:

• Cancer
• Infectious Diseases
• Metabolic Diseases
• Neurological Diseases
• Other

RNA Targeting Small Molecule Drug Discovery Market, By End Users:

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

RNA Targeting Small Molecule Drug Discovery Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Targeting Small Molecule Drug Discovery Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNA Targeting Small Molecule Drug Discovery Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 5.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.4. By Company (2022)
• 5.3. Market Map
  • 5.3.1. By Indication
  • 5.3.2. By End Users
  • 5.3.3. By Region

6. North America RNA Targeting Small Molecule Drug Discovery Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 6.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By End User

7. Europe RNA Targeting Small Molecule Drug Discovery Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 7.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By End User
  • 7.3.2. Germany RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By End User

8. Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 8.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By End User
  • 8.3.2. India RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By End User

9. South America RNA Targeting Small Molecule Drug Discovery Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 9.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By End User

10. Middle East and Africa RNA Targeting Small Molecule Drug Discovery Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 10.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global RNA Targeting Small Molecule Drug Discovery Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Financials (As Reported)
• 15.5. Key Personnel
• 15.6. SWOT Analysis
  • 15.6.1 Accent Therapeutics.
  • 15.6.2 Anima Biotech Inc.
  • 15.6.3 Arrakis Therapeutics.
  • 15.6.4 AstraZeneca Plc.
  • 15.6.5 Epics Therapeutics.
  • 15.6.6 Expansion Therapeutics.
  • 15.6.7 F. Hoffmann-La Roche Ltd.
  • 15.6.8 H3 Biomedicine Inc.
  • 15.6.9 PTC Therapeutics.
  • 15.6.10 Ribometrix.
  • 15.6.11 Servier Laboratories.
  • 15.6.12 Skyhawk Therapeutics, Inc.

16. Strategic Recommendations